Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06568198 · ClinicalTrials.gov registry record · Phase 2

Modulation Effect of tACS on Chronic Low Back Pain

A Phase 2 study of Chronic Low Back Pain, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT06568198: Recruiting Phase 2 study of Chronic Low Back Pain, sponsored by Massachusetts General Hospital.

NCT06568198 is a Phase 2 study of Chronic Low Back Pain that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06568198, a Phase 2 study of Chronic Low Back Pain, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

Investigating the modulation effect of tACS

Primary Outcome

EEG/MEG data will be collected to measure alpha activity.

Conditions Studied

Interventions

  • DEVICE Sham tACS
  • DEVICE Real tACS

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-08-25
Est. Completion 2028-02-28
Phase Phase 2
Massachusetts General Hospital

2,032 total trials

What NCT06568198 shows while recruiting

NCT06568198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Sham tACS is the first listed.

NCT06568198 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06568198 about?

NCT06568198 is a clinical study titled "Modulation Effect of tACS on Chronic Low Back Pain". Investigating the modulation effect of tACS

What is the current status of trial NCT06568198?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-08-25. Estimated completion is 2028-02-28.

What conditions does trial NCT06568198 study?

This clinical trial studies the following conditions: Chronic Low Back Pain.

What interventions are being tested in trial NCT06568198?

The interventions under investigation include: Sham tACS (DEVICE), Real tACS (DEVICE).

Who is sponsoring clinical trial NCT06568198?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06568198 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06568198's enrollment target sits among peer trials

80 34th of 71 higher than 38 of 71 other Chronic Low Back Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06568198, the US trial registry maintained by the National Library of Medicine. NCT06568198 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.